Binfeng Liu
Overview
Explore the profile of Binfeng Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
199
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li L, Feng C, Zhang W, Qi L, Liu B, Wang H, et al.
ACS Appl Mater Interfaces
. 2024 Oct;
16(44):59721-59737.
PMID: 39460726
Cisplatin, a frontline chemotherapeutic agent against cancer, faces challenges in clinical application due to significant toxicities and suboptimal efficacy. Renal toxicity, a dose-limiting factor of cisplatin, results from multifactorial processes...
2.
Zhang Z, Liu B, Mei L, Chen R, Zhou H, Li Z
Int Immunopharmacol
. 2024 Oct;
143(Pt 1):113312.
PMID: 39405927
Background: The Ras-responsive element binding protein 1 (RREB1) is a transcription factor involved in various biological processes. Notably, RREB1 plays a role in tumor immunity by regulating tumor-related gene expression,...
3.
Zhang Z, Liu B, Lin Z, Mei L, Chen R, Li Z
FASEB J
. 2024 Jul;
38(14):e23783.
PMID: 39037571
Secreted phosphoprotein 1 (SPP1), also known as osteopontin, is a phosphorylated protein. High SPP1 expression levels have been detected in multiple cancers and are associated with poor prognosis and reduced...
4.
Zhang W, Li W, Yin C, Feng C, Liu B, Xu H, et al.
Cancer Res
. 2024 Jun;
84(17):2873-2887.
PMID: 38900943
Chemoresistance is one of the major causes of poor prognosis in osteosarcoma. Alternative therapeutic strategies for osteosarcoma are limited, indicating that increasing sensitivity to currently used chemotherapies could be an...
5.
Wang S, Wang H, Li C, Liu B, He S, Tu C
MedComm (2020)
. 2024 Mar;
5(3):e489.
PMID: 38469550
Cancer is a major cause of death globally, and traditional treatments often have limited efficacy and adverse effects. Immunotherapy has shown promise in various malignancies but is less effective in...
6.
Liu B, He S, Li C, Li Z, Feng C, Wang H, et al.
Front Immunol
. 2024 Jan;
14:1321616.
PMID: 38264665
Background: Soft tissue sarcoma (STS) is a highly heterogeneous musculoskeletal tumor with a significant impact on human health due to its high incidence and malignancy. Long non-coding RNA (lncRNA) and...
7.
Tu C, Liu B, Li C, Feng C, Wang H, Zhang H, et al.
MedComm (2020)
. 2023 Sep;
4(5):e369.
PMID: 37731946
Soft tissue sarcoma (STS) is an uncommon malignancy that often carries a grim prognosis. Trophinin-associated protein (TROAP) is augmented in a variety of tumors and can affect tumor proliferation. Nevertheless,...
8.
Liu B, Li C, Feng C, Wang H, Zhang H, Tu C, et al.
Front Immunol
. 2023 Jun;
14:1178436.
PMID: 37377953
Background: Soft tissue sarcoma (STS) is a class of malignant tumors originating from mesenchymal stroma with a poor prognosis. Accumulating evidence has proved that angiogenesis is an essential hallmark of...
9.
Tang J, Zhang J, Lu Y, He J, Wang H, Liu B, et al.
Biomark Res
. 2023 Apr;
11(1):42.
PMID: 37069649
N6-methyladenosine (mA) is considered as the most common and important internal transcript modification in several diseases like type 2 diabetes, schizophrenia and especially cancer. As a main target of mA...
10.
Liu B, He S, Li C, Feng C, Wang H, Zhang H, et al.
Front Genet
. 2023 Apr;
14:1161791.
PMID: 37065471
Soft tissue sarcoma (STS) is a highly malignant tumor with a dismal prognosis. Presently, the dysregulation of fatty acid metabolism has received increasing attention in tumor research, but fewer reports...